Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Table 5 Utility values for the health states and disutility values associated with adverse events

	Utility value	Range	Distribution	Source
Progression-free (no AE)
1st -line afatinib and pemetrexed-cisplatin	0.71	0.67 to 0.76	Beta	[c]^a
Progressive disease (no AE)
2nd -line afatinib and pemetrexed-cisplatin	0.67	0.59 to 0.75	Beta	[c]^a
3rd-line/ Best supportive care	0.59	0.42 to 0.77	Beta	[c]^a
Adverse events
Neutropenia	−0.090	0.059 to 0.120	Beta	[d]
Fatigue	−0.074	0.037 to 0.110	Beta	[d]
Anaemia^b	−0.074	0.037 to 0.110	Beta	[d]
Nausea & vomiting	−0.048	0.016 to 0.080	Beta	[d]
Diarrhoea	−0.047	0.016 to 0.077	Beta	[d]
Rash	−0.033	0.010 to 0.055	Beta	[d]

^aThe utility was then weighted by the proportion of time spent in the health state
^bAssumed from the disutility for fatigue
Source: ^cChouaid et al, [20]; ^dNafees et al, [21]

ISSN: 1471-2407